Across TCGA pan-cancer cohorts, TEX264 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TEX264 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher TEX264 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TEX264 expression acts as an unfavorable survival marker.
BLCA, LUAD, and ESCA are the cancer types where TEX264 Mutation most reproducibly stratifies survival.